Back

Pomerantz investigates Dr. Reddy’s after 9.4% stock drop tied to semaglutide batches

Verifying
  • Pomerantz LLP is investigating Dr. Reddy’s and certain officers and directors on investors’ behalf.
  • ₹2.4 billion provision for rejected semaglutide batches contributed to $0.06 fiscal first-quarter earnings per share.
  • Dr. Reddy’s shares fell 9.4% to $11.38 on July 22, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.